Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

271.13 +3.72 (+1.39%)
Official Closing Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
(PEN) - Analyzing Penumbra's Short Interest
Via Benzinga
Breaking Down Penumbra: 11 Analysts Share Their Views
Via Benzinga
How Is The Market Feeling About Penumbra?
Via Benzinga
Key Takeaways From Penumbra Analyst Ratings
Via Benzinga
Looking Into Penumbra's Recent Short Interest
Via Benzinga
Why Penumbra Stock Zoomed 4% Higher Today
The latest news from the lab, plus an analyst's bullish move, combined to put some zip in the company's shares. 
Via The Motley Fool
Critical Insights From Penumbra Analyst Ratings: What You Need To Know
Via Benzinga
Peering Into Penumbra's Recent Short Interest
Via Benzinga
Why NYSE:PEN Is a Standout High-Growth Stock in a Consolidation Phase.
PENUMBRA INC (NYSE:PEN)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
Analyst Ratings For Penumbra
Via Benzinga
Deep Dive Into Penumbra Stock: Analyst Perspectives (13 Ratings)
Via Benzinga
Why Penumbra Stock Zoomed Nearly 5% Higher Today
The company might just be the right kind of business operating at the right time in history. 
Via The Motley Fool
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Pinterest Issues Weak Revenue Forecast, Joins Groupon, O-I Glass And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning! 
Via InvestorPlace
Key Takeaways From Penumbra Analyst Ratings
Via Benzinga
(PEN) - Analyzing Penumbra's Short Interest
Via Benzinga
Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Peering Into Penumbra's Recent Short Interest
Via Benzinga
Looking Into Penumbra's Recent Short Interest
Via Benzinga
Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility
Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD) 
Via Benzinga
Topics Economy
Exposures Interest Rates
PEN Stock Earnings: Penumbra Beats EPS, Beats Revenue for Q2 2024
PEN stock results show that Penumbra beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
The Latest Analyst Ratings For Penumbra
Via Benzinga
Penumbra Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Top 3 Health Care Stocks That Could Blast Off In June
Via Benzinga
PEN Stock Earnings: Penumbra Beats EPS, Beats Revenue for Q1 2024
PEN stock results show that Penumbra beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Don't Overlook These Top Medical Stocks As Q1 Earnings Approach
While the tech sector has led the Q1 earnings season, investors shouldn’t overlook these top medical stocks. To that point, the growth and expansion of Ligand Pharmaceuticals, Oscar Health, and... 
Via Talk Markets
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.